243 related articles for article (PubMed ID: 24022270)
1. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Havrdova E; Giovannoni G; Stefoski D; Forster S; Umans K; Mehta L; Greenberg S; Elkins J
Mult Scler; 2014 Apr; 20(4):464-70. PubMed ID: 24022270
[TBL] [Abstract][Full Text] [Related]
2. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
[TBL] [Abstract][Full Text] [Related]
3. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
4. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
[TBL] [Abstract][Full Text] [Related]
5. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Giovannoni G; Radue EW; Havrdova E; Riester K; Greenberg S; Mehta L; Elkins J
J Neurol; 2014 Feb; 261(2):316-23. PubMed ID: 24375015
[TBL] [Abstract][Full Text] [Related]
6. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J
Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
8. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
[TBL] [Abstract][Full Text] [Related]
9. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
[TBL] [Abstract][Full Text] [Related]
10. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ
Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab and its use in multiple sclerosis treatment.
Milo R; Osherov M
Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
[TBL] [Abstract][Full Text] [Related]
12. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
13. Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Phillips G; Guo S; Bender R; Havrdová E; Proskorovsky I; Vollmer T
Mult Scler Relat Disord; 2016 Mar; 6():66-72. PubMed ID: 27063626
[TBL] [Abstract][Full Text] [Related]
14. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang LN; Zhan S; Xia Y
Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
[TBL] [Abstract][Full Text] [Related]
17. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
Sheridan JP; Robinson RR; Rose JW
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):9-19. PubMed ID: 24308792
[TBL] [Abstract][Full Text] [Related]
19. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
Osherov M; Milo R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]